August 2023 - TinyGems

WednesdayAug 30, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation Amid Preparations for Planned Acclaim-3 Clinical Trial

Genprex recently received orphan drug designation for its lead drug candidate REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid) for the treatment of small cell lung cancer (“SCLC”) The company also celebrated receipt of its third Fast Track Designation (“FTD”), granted by the FDA, this time for REQORSA Immunogene Therapy, in combination with Tecentriq in patients with extensive stage small cell lung cancer (“ES-SCLC”) The orphan drug designation (“ODD”) in combination with the FTD is an indication of the great need for better treatment options for patients with ES-SCLC, and non-small cell lung cancer (“NSCLC”), according to Genprex President, Chairman, and CEO Rodney…

WednesdayAug 30, 2023 9:00 am

GEMXX Corp.’s (GEMZ) Strategic Investments Pay Off, as Company Positions itself as a World Class Producer and Distributor of Gemstones and Jewelry

GEMXX recently announced that new investments had strengthened its financial position and would allow it to attract further investment over the next 12 months The announcement followed the acquisition of a 50% ownership stake in Crazy Horse Mining Inc., whose assets include a 100% interest in the Snow Creek and Rosella Creek gold projects in British Columbia Initial production results on the Snow Creek site prop GEMXX to scale up gold production, having announced plans to ramp up processing to approximately 1,000 cubic yards of gold-bearing ore per day GEMXX (OTC: GEMZ), a publicly traded vertically integrated company specializing in…

MondayAug 28, 2023 9:00 am

Jewelry Maker GEMXX Corp. (GEMZ) Ramps Up Production at Canadian Gold Site

GEMXX Corporation is a unique vertically integrated jewelry producer, focused on managing costs in-house by mining its own gold and gemstones via its Canadian mine resources for its many jewelry products GEMXX has been engaged this year in bringing one of its British Columbia gold ore sites up to full production The company recently announced the encouraging results of gold ore processed from surface materials stockpiled during site construction, amounting to 0.86 ounces per 100 cubic yards GEMXX will add the gold processed from the site to fossilized, iridescent Ammolite gemstones from its Alberta resources, as the materials for its…

WednesdayAug 23, 2023 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Is ‘One to Watch’

For the quarter ended June 30, 2023, RVLP reported net sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year period; this strategy is designed to extend cash runway for future business development and changes in the company’s marketing mix The company’s marketing partner, Santen, has commenced the required registrational trial for UPNEEQ(R) in Japan and plans to begin the same in China in 2023 UPNEEQ(R) has strong U.S. intellectual property protection, with patents extending to 2039 RVL Pharmaceuticals launched its prescription ecommerce platform, Elevate, in July 2023, allowing providers…

TuesdayAug 22, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Affirms Product Superiority in Its 2023 Human Oral Nicotine Study, NIC-H22-1

Lexaria’s NIC-H22-1 study proved that its patented DehydraTECH(TM)-nicotine tobacco-free pouch was statistically significantly faster-acting than alternatives The study, which involved 36 participants, embraced a randomized, double-blind, cross-over study design It also affirmed Lexaria's product superiority while also showing DehydraTECH’s potential Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released results from its 2023 human oral nicotine study NIC-H22-1. Of note was its patented DehydraTECH(TM)–nicotine tobacco-free pouch product superiority, particularly when pitted against world-leading brands ZYN(R) and on!(R). The study proved that Lexaria’s product was statistically significantly faster than the two alternatives in the median time…

MondayAug 21, 2023 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Strategic Updates Concerning Patented DehydraTECH(TM) Technology

Lexaria's human oral nicotine study, NIC-H22-1, comparing world-leading brands and the company's DehydraTECH(TM)-Nicotine tobacco-free pouch, reported positive results, including higher pleasurable effects and reduced negative effects A new patent has been granted to Lexaria and is strategically important to the company's oral nicotine sector research and development efforts Lexaria continues to research diabetes control and weight loss with its DehydraTECH(TM)-CBD, announcing favorable animal study results and the intent to develop a human clinical study Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced updates regarding its patented DehydraTECH(TM) technology – which improves the way that…

TuesdayAug 15, 2023 9:45 am

GEMXX Corp. (GEMZ) Expanding Brand Awareness As It Strengthens Mine Project Financing

GEMXX Corporation, a U.S. corporation with mines in Canada, is a mine-to-jewelry production innovator, drawing on its mining assets for the gold and gems it uses in colorful jewelry GEMXX recently engaged the marketing and brand expertise of Hybrid Financial Ltd. as the company seeks to expand awareness of its novel operations in gold and rare gem Ammolite GEMXX similarly is working with InvestorBrandNetwork (“IBN”) to expand awareness of the company through IBN’s syndication outlets, wire services and other corporate communication efforts The company is preparing to perform National Instrument 43-101 and S-K 1300-compliant Resource Reports on two of its…

ThursdayAug 10, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Intent for Human Clinical Study for Diabetes and Weight Loss Following Positive DehydraTECH(TM)-CBD Results in Animals

Lexaria’s patented DehydraTECH(TM)-CBD achieved promising results for diabetes control and weight loss in animals during the pre-clinical animal study DIAB-A22-1 The weight loss drug market was valued at $1.90 billion in 2021 and is expected to reach $13.26 billion by 2029, growing at a CAGR of 24.7% Many drugs used to control diabetes have produced results in managing obesity, which Lexaria plans to leverage with its DehydraTECH(TM) technology Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, recently announced its intent to conduct a human clinical study to examine its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for diabetes control…

TuesdayAug 08, 2023 9:45 am

GEMXX Corp. (GEMZ) Announces Significant Progress Regarding Financing for Gold and Ammolite Mining Operations

The company offers an approach that gives them a cost-saving edge over other producers in the market Preliminary discussions have been made to shortlist engineering firms capable of conducting the necessary SK-1300 technical reports for the company’s newest gold and Ammolite assets – with anticipated completion by the end of FY-2023 GEMXX is participating in Regulation A financing, and interested investors, shareholders, institutions, and financiers, are urged to visit the company’s website for more information GEMXX (OTC: GEMZ), a mine-to-market enterprise specializing in gold, gemstone, and jewelry production, recently announced that it has made significant progress in its efforts to…

TuesdayAug 08, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates ‘Strategically Important’ New Patent Granted in the US

Lexaria recently celebrated the receipt of its 35th overall granted patent worldwide when the USPTO recently awarded US patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine” The company described the new patent as “strategically important” The patent positions the company to tap into the growing oral nicotine market and offers protection in one of the world’s leading oral nicotine markets This patent could also lead to additional subsequent patents from within this family Lexaria’s DehydraTECH-nicotine formulation is patent granted for oral nicotine delivery in the US, Canada, and Australia When Lexaria Bioscience (NASDAQ: LEXX), a global innovator…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717

Month: August 2023